Allucent, a global specialty CRO tailored for small and mid-sized biopharma companies, has appointed new therapeutic strategy leaders across its Allucent Centers of Expertise (ACEs) in areas such as oncology, neuroscience, cardiometabolic diseases, and immunology & inflammation, as well as advanced therapeutics for rare diseases and cell and gene therapy. These appointments aim to enhance integrated drug development by combining deep expertise with operational capabilities, addressing the complexity of drug development. By integrating strategy and execution, Allucent is positioned to accelerate program advancement and streamline decision-making for its clients.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/allucent-expands-strategic-leadership-to-advance-centers-of-expertise-and-fortify-specialty-cro-position
